Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway

Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still un...

Full description

Bibliographic Details
Main Authors: Mengmeng Wang, Shuqiao Xing, Jiamei Jia, Weiquan Zeng, Jia Lei, Yiming Qian, Zhenrong Xiong, Xin Wang, Liying Cao, Yongjie Wang, Ying Wang, Yuanyuan Jiang, Zhihui Huang
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223002500
_version_ 1797857725688840192
author Mengmeng Wang
Shuqiao Xing
Jiamei Jia
Weiquan Zeng
Jia Lei
Yiming Qian
Zhenrong Xiong
Xin Wang
Liying Cao
Yongjie Wang
Ying Wang
Yuanyuan Jiang
Zhihui Huang
author_facet Mengmeng Wang
Shuqiao Xing
Jiamei Jia
Weiquan Zeng
Jia Lei
Yiming Qian
Zhenrong Xiong
Xin Wang
Liying Cao
Yongjie Wang
Ying Wang
Yuanyuan Jiang
Zhihui Huang
author_sort Mengmeng Wang
collection DOAJ
description Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still unclear. In this study, we found that angelicin inhibited the proliferation of GBM by inducing the cell cycle arrested in G1 phase and suppressed the migration of GBM cells in vitro. Mechanically, we found that angelicin downregulated the expression of YAP and decreased the nuclear localization of YAP, and suppressed the expression of β-catenin. Furthermore, overexpression of YAP partially restored the inhibitory effect of angelicin on GBM cells in vitro. Finally, we found that angelicin could inhibit the growth of tumor and reduce the expression of YAP in the subcutaneous xenograft model of GBM in nude mice and the syngeneic intracranial orthotopic model of GBM in C57BL/6 mice. Taken together, our results suggest that the natural product angelicin exerts its anticancer effects on GBM via YAP signaling pathway, and is expected to be a promising compound for the treatment of GBM.
first_indexed 2024-04-09T21:02:31Z
format Article
id doaj.art-fe9ac1ce0c08426c90b3f381f1abde7a
institution Directory Open Access Journal
issn 0753-3322
language English
last_indexed 2024-04-09T21:02:31Z
publishDate 2023-05-01
publisher Elsevier
record_format Article
series Biomedicine & Pharmacotherapy
spelling doaj.art-fe9ac1ce0c08426c90b3f381f1abde7a2023-03-29T09:22:26ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-05-01161114462Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathwayMengmeng Wang0Shuqiao Xing1Jiamei Jia2Weiquan Zeng3Jia Lei4Yiming Qian5Zhenrong Xiong6Xin Wang7Liying Cao8Yongjie Wang9Ying Wang10Yuanyuan Jiang11Zhihui Huang12School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaClinical Research Center, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China; Corresponding author.School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Corresponding authors at: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Corresponding authors at: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still unclear. In this study, we found that angelicin inhibited the proliferation of GBM by inducing the cell cycle arrested in G1 phase and suppressed the migration of GBM cells in vitro. Mechanically, we found that angelicin downregulated the expression of YAP and decreased the nuclear localization of YAP, and suppressed the expression of β-catenin. Furthermore, overexpression of YAP partially restored the inhibitory effect of angelicin on GBM cells in vitro. Finally, we found that angelicin could inhibit the growth of tumor and reduce the expression of YAP in the subcutaneous xenograft model of GBM in nude mice and the syngeneic intracranial orthotopic model of GBM in C57BL/6 mice. Taken together, our results suggest that the natural product angelicin exerts its anticancer effects on GBM via YAP signaling pathway, and is expected to be a promising compound for the treatment of GBM.http://www.sciencedirect.com/science/article/pii/S0753332223002500AngelicinGBMYAPProliferationCell cycleMigration
spellingShingle Mengmeng Wang
Shuqiao Xing
Jiamei Jia
Weiquan Zeng
Jia Lei
Yiming Qian
Zhenrong Xiong
Xin Wang
Liying Cao
Yongjie Wang
Ying Wang
Yuanyuan Jiang
Zhihui Huang
Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
Biomedicine & Pharmacotherapy
Angelicin
GBM
YAP
Proliferation
Cell cycle
Migration
title Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
title_full Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
title_fullStr Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
title_full_unstemmed Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
title_short Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
title_sort angelicin impedes the progression of glioblastoma via inactivation of yap signaling pathway
topic Angelicin
GBM
YAP
Proliferation
Cell cycle
Migration
url http://www.sciencedirect.com/science/article/pii/S0753332223002500
work_keys_str_mv AT mengmengwang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT shuqiaoxing angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT jiameijia angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT weiquanzeng angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT jialei angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT yimingqian angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT zhenrongxiong angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT xinwang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT liyingcao angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT yongjiewang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT yingwang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT yuanyuanjiang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway
AT zhihuihuang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway